Retroviral Recombination, RNA Dimers & Multiple Drug Resistant HIV-1
Funder
National Health and Medical Research Council
Funding Amount
$405,017.00
Summary
The emergence of multiple drug resistant strains of HIV-1 has threatened the continue success of current clinical treatment to suppress virus propagation. Retroviruses, such as HIV-1, can reshuffle its two copies of genetic materials during the viral replication process, which leads to the production of offspring viruses that contain a mixture of the parental genetic materials. This process of genetic information reshuffling is believed to be important for the generation of multiple drug resista ....The emergence of multiple drug resistant strains of HIV-1 has threatened the continue success of current clinical treatment to suppress virus propagation. Retroviruses, such as HIV-1, can reshuffle its two copies of genetic materials during the viral replication process, which leads to the production of offspring viruses that contain a mixture of the parental genetic materials. This process of genetic information reshuffling is believed to be important for the generation of multiple drug resistant strains of HIV-1. The objective of this proposal is to define the parameters that regulate the reshuffling of HIV-1 genetic materials and to design novel tools to inhibit the production of multiple drug resistant HIV-1.Read moreRead less
Role Of Conformational Change In Activation Of The Growth Hormone Receptor
Funder
National Health and Medical Research Council
Funding Amount
$242,545.00
Summary
Growth hormone is an important hormone therapeutic for treating dwarfism. Recently, many new therapeutic applications for growth hormone have been discovered, particularly in relation to its role as an anabolic agent. These include post surgery recovery, enhanced bone fracture healing, Crohns disease, dilated cardiomyopathy, infertility and of course, ageing. This project seeks to find out how growth hormone sends its signal into the target cell through its surface receptor. It is believed that ....Growth hormone is an important hormone therapeutic for treating dwarfism. Recently, many new therapeutic applications for growth hormone have been discovered, particularly in relation to its role as an anabolic agent. These include post surgery recovery, enhanced bone fracture healing, Crohns disease, dilated cardiomyopathy, infertility and of course, ageing. This project seeks to find out how growth hormone sends its signal into the target cell through its surface receptor. It is believed that the primary event in signalling is the ability of the hormone to bring two receptors together (receptor dimerization). However, it may be that the receptor already is dimerized, and the role of the hormone is to induce a specific change in shape of the receptor, which transfers the signal of hormone binding into the cell to initiate signalling to the genome. We have good evidence that a specific shape change is required for activation of an important signalling pathway by growth hormone, and the closely structurally related receptor for erythropoietin is already dimerized before hormone binds. We want to find out exactly how the shape change acts, and whether the receptor is predimerized. This information is vital for designing small orally active mimics of growth hormone which could be of great value as an anabolic supplement for the frail elderly.Read moreRead less
Human immunodeficiency virus type 1 (HIV-1) is the causative agent of AIDS. Recent advances with combination antiretroviral therapy have prolonged the survival time of HIV-1 infected patients, and provideed two important hints for a strategy to effectively treat this disease. First, administration of a combination of antiretroviral agents that target different stages of the viruses life cycle improves the clinical status of HIV-1 infected patients; and second, the formation of viral particles du ....Human immunodeficiency virus type 1 (HIV-1) is the causative agent of AIDS. Recent advances with combination antiretroviral therapy have prolonged the survival time of HIV-1 infected patients, and provideed two important hints for a strategy to effectively treat this disease. First, administration of a combination of antiretroviral agents that target different stages of the viruses life cycle improves the clinical status of HIV-1 infected patients; and second, the formation of viral particles during the HIV-1 replication cycle is an effective target for antiretroviral treatment, as demonstrated by the potency of drugs called protease inhibitors. A virus such as HIV is composed of viral proteins as well as genetic material called RNA. Two strands of viral RNA come together during the formation of HIV-1 in a process callered dimerization. It may be possible to interfere with RNA dimerization thus inhibiting HIV replication. This would provide a new target for HIV therapy. In order to do this, the process of RNA dimerization needs to be understood.The focus of this project is to define the mechanism of HIV-1 RNA dimerization, and to identify factors that are critical for virion RNA dimerization. Understanding the mechanism of virion RNA dimerization is likely to provide novel therapeutic target for the development of effective antiviral agents.Read moreRead less
Novel G-protein Coupled Receptor Interactions And Complexes With Distinct Function And Pharmacology
Funder
National Health and Medical Research Council
Funding Amount
$246,760.00
Summary
G protein coupled receptors (GPCRs) are the target in the human body for most of today's medicines. Almost all pharmaceutical companies market drugs that are GPCR agonists or antagonists aimed at diverse disease states. Our research is focused on the molecular basis of drug recognition and signalling by GPCRs. We use genetic engineering techniques to create new receptors and mutant receptors in order to identify the functional domains of these signalling molecules. We have recently established a ....G protein coupled receptors (GPCRs) are the target in the human body for most of today's medicines. Almost all pharmaceutical companies market drugs that are GPCR agonists or antagonists aimed at diverse disease states. Our research is focused on the molecular basis of drug recognition and signalling by GPCRs. We use genetic engineering techniques to create new receptors and mutant receptors in order to identify the functional domains of these signalling molecules. We have recently established a novel approach based on proximity-dependent fluorescent technologies to explore receptor interactions and have described the formation of functional G-protein coupled complexes in living cells. This project is to discover new receptor combinations which could potentially affect signalling pathways and redirect cellular responses. Investigation of the mechanisms involved in turning on and off the body s response to stimuli would provide valuable information for drug design and treatment of GPCR-related conditions. We have chosen to use two GPCRs as models for our study of the mechanisms controlling receptor driven cellular responses and the interactions between cellular components-proteins behind this control. Firstly, the gonadotropin releasing hormone receptor (GnRHR), a protein located in the pituitary which is pivotal in the control of reproduction and secondly, the thyrotropin releasing hormone receptor (TRHR), similarly located and involved in modulating thyroid and metabolic function. We will investigate the way these receptors interact with other cellular proteins in order for them to function. Ultimately this will provide a better understanding of how these clinically important proteins function and pave the way for the development of clinical applications that target these receptor systems, resulting in the effective treatment of a wide range of conditions and diseases, including pain, migraine, certain forms of cancer, neurological and reproductive disorders.Read moreRead less